In this cross-sectional study of 729 female patients with a first diagnosis of breast cancer who participated in a universal genetic testing program, 5.3% had germline pathogenic variants in BRCA1/2 or PALB2, and 1.8% were considered eligible for poly(adenosine diphosphate–ribose) polymerase inhibitors based on their genetic testing result. This evidence concerns the gene PALB2 and breast cancer.